EUVIMEDEUVIMED entdecken
Open Access

Altered cleavage of human factor VIII at the B-domain and acidic region 3 interface enhances expression after gene therapy in hemophilia A mice

Giang N Nguyen, Jonathan R Lindgren, Maria C Seleme, Samita Kafle, Catherine B Zander, X Long Zheng, Denise E Sabatino

Journal of Thrombosis and Haemostasis · 2023-08 · 21 (8) · 2101-2113

DOI: 10.1016/j.jtha.2023.04.012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2023-08. Verfasst von Giang N Nguyen und 6 weiteren Autor:innen. Beteiligte Einrichtung: The Raymond G. Perelman Center for Cellular and Molecular Therapeutics, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Factor VIII, Hemophilia A. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Variants of human factor VIII (hFVIII) have been developed to further understand the structure and function of hFVIII and improve gene-based therapeutics. We have previously characterized several hFVIII variants of the furin cleavage site (1645-1648) with improved secretion. We have also identified a second cleavage site in the acidic region 3 (a3) (1657-1658) that becomes the primary hFVIII intracellular cleavage position in the absence of the furin site. We tested a hypothesis that modification of this site may confer additional functional advantages to hFVIII. OBJECTIVES: The aim of this study was to conduct the biochemical and functional characterization of hFVIII variants of the furin cleavage site, the a3 cleavage site, or in combination, both in vitro and in vivo after AAV mediated gene therapy. METHODS: Recombinant hFVIII variants of the furin cleavage site (hFVIII-Δ3), the a3 cleavage site (hFVIII-S1657P/D1658E [SP/DE]), or in combination (hFVIII-Δ3-SP/DE) were purified and characterized in vitro and in vivo. RESULTS: Recombinant hFVIII-Δ3, hFVIII-SP/DE, and hFVIII-Δ3-SP/DE variants all had comparable specific activity to B-domain deleted (BDD) hFVIII. Hemophilia A mice tolerant to hFVIII did not develop immune responses to hFVIII after protein challenge with these variants or after adeno-associated virus (AAV) delivery. Following AAV delivery, hFVIII-Δ3-SP/DE resulted in expression levels that were 2- to 5-fold higher than those with hFVIII-BDD in hemophilia A mice. CONCLUSION: The novel hFVIII-Δ3-SP/DE variant of the furin and a3 cleavage sites significantly improved secretion compared with hFVIII-BDD. This key feature of the Δ3-SP/DE variant provides a unique strategy that can be combined with other approaches to further improve factor VIII expression to achieve superior efficacy in AAV-based gene therapy for hemophilia A.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Factor VIIIHemophilia AHumansAnimalsMiceFurinProtein DomainsGenetic TherapyGenetic Vectors

Stichwörter der Autor:innen

adeno-associated viral vectorblood coagulation factorsfactor VIIIgenetic therapyhemophilia

Substanzen

Factor VIIIFurin

Autor:innen und Institutionen

  • The Raymond G. Perelman Center for Cellular and Molecular Therapeutics, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Department of Pathology, University of Alabama at Birmingham School of Medicine, University of Alabama, Birmingham, Alabama, USA.
  • Department of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas City, Kansas, USA; Institute of Reproductive Medicine and Developmental Science, The University of Kansas Medical Center,…
  • The Raymond G. Perelman Center for Cellular and Molecular Therapeutics, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA; Department of Pediatrics, Division of Hematology, Perelman School of Medi…

Förderung

  • NHLBI NIH HHS
  • National Institutes of Health

Zitieren

APA

Nguyen, G. N., Lindgren, J. R., Seleme, M. C., Kafle, S., Zander, C. B., Zheng, X. L., & Sabatino, D. E. (2023). Altered cleavage of human factor VIII at the B-domain and acidic region 3 interface enhances expression after gene therapy in hemophilia A mice. Journal of Thrombosis and Haemostasis, 21(8), 2101-2113. https://doi.org/10.1016/j.jtha.2023.04.012

Vancouver

Nguyen GN, Lindgren JR, Seleme MC, Kafle S, Zander CB, Zheng XL, et al. Altered cleavage of human factor VIII at the B-domain and acidic region 3 interface enhances expression after gene therapy in hemophilia A mice. Journal of Thrombosis and Haemostasis. 2023;21(8):2101-2113. doi:10.1016/j.jtha.2023.04.012

BibTeX
@article{Nguyen2023,
  author = {Nguyen, Giang N and Lindgren, Jonathan R and Seleme, Maria C and Kafle, Samita and Zander, Catherine B and Zheng, X Long and Sabatino, Denise E},
  title = {Altered cleavage of human factor VIII at the B-domain and acidic region 3 interface enhances expression after gene therapy in hemophilia A mice},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2023},
  volume = {21},
  number = {8},
  pages = {2101--2113},
  doi = {10.1016/j.jtha.2023.04.012}
}
Kostenlos starten →